focus -WSS

focus

author：entertainment 2025-10-01 00:14:24 - browse：72796

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： The Karikó problem: Lessons for funding basic research

WSS

Flu, Covid vaccination rates decline, new survey data show

CDC picks Alphabet's Verily for wasterwater surveillance contract

2023 Nobel Prize in Medicine goes to Karikó and Weissman

RSV injection headlines need to be accurate for good uptake

RSV injection headlines need to be accurate for good uptake

The stability of $0 premiums in Medicare Advantage

knowledge

focus

knowledge

Walensky prepares to leave CDC — and Congress — behind

CDC picks Alphabet's Verily for wasterwater surveillance contract

Supreme Court strikes down use of affirmative action

Flu, Covid vaccination rates decline, new survey data show

Affirmative action in medical school literally saved lives

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

The high cost of giving birth even with insurance

Study points to new risk in gene therapy death of Terry Horgan

Medicare proposal to cover medical devices draws a mixed reaction

The stability of $0 premiums in Medicare Advantage

hotspot

With Roe v Wade overturned, abortion providers work to adapt

Congress extends some pandemic preparedness programs

2023 Nobel Prize in Medicine goes to Karikó and Weissman

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Flu, Covid vaccination rates decline, new survey data show

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

focus

knowledge

focus

Wikipedia